ParkCell is a life science company operating in the field of neuroscience. We are specialized in the neurodegenerative disorder Parkinson’s disease. Our primary program is dedicated to the development of a potentially curative cell-based therapy for the disease and has the potential of being classified as an advanced therapy medicinal products (ATMPs).

Our novel cell-based technology includes replacement, by autologous transplantation, of lost brain cells in Parkinson’s disease patients with new cells, and these transplanted cells have been shown to produce important transmitter molecules lost in the disease. Our technology is not based on stem cells and ParkCell has established and validated methods for harvesting, purifying, and expanding the specific cells to be transplanted.

We have in vitro results as well as in vivo animal data supporting that the transplanted cells will be viable and restore lost central nervous system (CNS) functions long-term after grafting to the specific and affected brain region of patients suffering from Parkinson’s disease. Through a standardized stereotactic surgical transplantation method, developed by members of the ParkCell team, the novel technology presents a highly promising and groundbreaking method for treatment of Parkinson’s disease.

Today, there is a large unmet need for treatments of Parkinson’s disease. The current treatments are old and only symptomatic and may only to some extent delay the unavoidable disease progression.

In general, the costs and risks associated with the development of an ATMP like ours are lower than for conventional drug development.

ParkCell also develops a novel biomarker-based diagnostic technology for early prediction of Parkinson’s disease long before patients start to display clinical symptoms.